Tiziana Life Science announced its intention not to engage in a capital raising activities for the immediate future. Following on from its news of the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis treated with nasal foralumab, the Company has decided not to engage in a capital raising activities for the immediate future.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Unveils New Biomarkers in Treatment of Progressive Multiple Sclerosis
- Tiziana Life Sciences announces discovery of new immune biomarkers
- Tiziana’s Nasal Therapy Reduces GLP-1 Side Effects
- Tiziana Life Sciences announces findings on nasal anti-CD3 monoclonal antibody
- Tiziana Life Sciences’ Foralumab Shows Promise in Neurodegenerative Disease Treatment